Shares of Novo Nordisk (NYSE:NVO) climbed 3.8% Thursday following a proposal from the U.S. Food and Drug Administration to remove semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposed change would prevent outsourcing facilities from compounding these drugs from bulk drug substances.
The FDA said it evaluated nominations for the three medicines and did not find a clinical need for outsourcing facilities to compound them from bulk substances. The 503B bulks list identifies which bulk drug substances outsourcing facilities may use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act.
Regulatory rationale
"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," said FDA Commissioner Marty Makary. "This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process."
The agency reported that, after reviewing the nominations, it did not locate sufficient evidence to place semaglutide, tirzepatide or liraglutide on the 503B bulks list. The FDA noted that clinical need determinations are governed by federal law requirements focused on patient safety and medical necessity.
Current compounding rules and potential impact
Under existing rules, outsourcing facilities generally cannot compound drugs from bulk drug substances unless the substance is on the 503B bulks list or the compounded drug appears on the FDA's drug shortage list. The proposed exclusion would therefore curtail the ability of compounding pharmacies and outsourcing facilities to produce lower-cost compounded versions of these weight-loss and diabetes therapies.
Next steps
The FDA is soliciting public comments electronically through June 29, 2026, prior to making a final determination on the proposal. The agency's public comment period provides stakeholders an opportunity to submit information the agency can consider before a conclusive decision is taken.
Market implications
Market observers see the move as favorable to makers of the branded formulations of the three drugs because it would likely limit competition from compounded alternatives. The immediate market reaction included a near 4% rise in Novo Nordisk shares on the day the proposal was announced.
Sections of the economy affected
- Pharmaceutical manufacturers producing branded versions of semaglutide, tirzepatide and liraglutide
- Outsourcing facilities and compounding pharmacies that might produce compounded alternatives
- Health care providers and patients who may be affected by access or pricing changes tied to compounding availability